Savolitinib is a highly selective mesenchymal-epithelial transition (MET) tyrosine kinase inhibitor (TKI). Based on its significant efficacy shown in clinical studies, savolitinib was conditionally approved for marketing in China on 22 June 2021, for the treatment of advanced non-small cell lung cancer (NSCLC) with MET 14 exon skipping mutation. Additionally, many studies showed that MET TKIs were equally effective in patients with advanced solid tumors with MET gene amplification or MET protein overexpression. Several relevant registered clinical studies are in progress. The most common adverse reactions (ARs) due to savolitinib administration are nausea, vomiting, peripheral edema, pyrexia, and hepatotoxicity. This consensus was developed through two rounds of extensive national surveys involving multidisciplinary experts in China, aiming to guide clinicians to prevent and treat various ARs scientifically, and improve the efficacy of the drug and the quality of life of patients.
Keyphrases
- advanced non small cell lung cancer
- tyrosine kinase
- adverse drug
- epidermal growth factor receptor
- end stage renal disease
- chemotherapy induced
- quality improvement
- small cell lung cancer
- newly diagnosed
- ejection fraction
- chronic kidney disease
- stem cells
- drug induced
- emergency department
- peritoneal dialysis
- palliative care
- electronic health record
- cross sectional
- genome wide
- copy number
- small molecule
- patient reported outcomes
- protein protein
- replacement therapy